+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Global Next-Generation Multi-Purpose Biosensors Market Set To Grow To $4.2bn By 2022

09 August 2018
Pharma

Visiongain has launched a new pharma report Global Next Generation Multi-Purpose Biosensors Market 2017-2027 : Nanomechanical, Optical, Electrochemical, Thermistor/Calorimetric, Patient Monitoring, Diagnostics, Therapeutics, Wearable, Implantable, Strip, Hospitals & Clinics, Home Diagnostics, Diagnostic Centres, Research Laboratories

Over the years, the next-generation multi-purpose biosensors market has witnessed a high adoption rate for advanced biosensors. This is due to the technological breakthroughs in the biosensors field such as the development of molecular markers, nanotechnology, microfluidics, and others. Moreover, the growing demand for cost-efficient, disposable and user-friendly devices has provided momentum for the growth of the next generation multi-purpose biosensors market.

The lead analyst of the report commented “The need for better diagnosis and treatment as well as the need to curb the cost of healthcare have led to the advent of next-generation multi-purpose biosensors. The advancements in nano and micro fabrication techniques have increased the use of next generation multi-purpose biosensors in healthcare. With features such as low cost, easy to use, and accurate results, these medical biosensors are the preferred options among patients and healthcare professionals. Therefore, many key players are involved in the development and commercialization of next generation multi-purpose biosensors.”

Leading companies featured in the report include Koninklijke Philips N.V., Abbott Laboratories, Universal Biosensors Inc., Bayer Healthcare AG, GE Healthcare, Biosensors International Group. Ltd., Medtronic plc, Nova Biomedical Corporation, Bio-Rad Laboratories Inc. and Sphere Medical Holding plc

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read